Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Pharmaceutical Ingredients Risperidone raw Powder
Product Overview:
Risperidone also binds to α1-adrenergic receptors and binds to H1-histaminergic receptors and α2-adrenergic receptors with low affinity. Risperidone does not bind to cholinergic receptors. Risperidone is a powerful D2 antagonist that can improve positive symptoms of schizophrenia, but it causes less inhibition of motor function and less tetanic fainting than classical antipsychotics. The balance of serotonin and dopamine antagonism in the central system can reduce the likelihood of extrapyramidal side effects and extend its therapeutic effect to the negative and affective symptoms of schizophrenia.
Pharmaceutical Ingredients Risperidone raw Powder Attributes
CAS:106266-06-2
MF:C23H27FN4O2
MW:410.48
EINECS:600-733-1
Specification: 99% min Risperidone
Sample:Risperidone Powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Pharmaceutical Ingredients Risperidone raw Powder Details
Risperidone Usage and Synthesis.
It is used to treat acute and chronic schizophrenia and various other psychotic states with clearly positive symptoms (e.g., hallucinations, fantasies, disorganization of thought, hostility, suspicion) and clearly negative symptoms (e.g., lethargy, emotional and social apathy, low speech). It may also reduce the emotional symptoms associated with schizophrenia (e.g., depression, guilt, anxiety). For patients who are effective in the acute phase of treatment, Vistone can continue to exert its clinical efficacy during the maintenance phase of treatment.
Drug interaction of Risperidone.
1. This product can antagonize the effect of levodopa and other dopamine agonists.
2. Amidazine and other liver enzyme inducers will reduce the plasma concentration of the active ingredient of this product. Once the use of amidazine or other liver enzyme inducers is discontinued, the dosage of this product should be redetermined and reduced if necessary.
3. Phenthiazide, tricyclic antidepressants and some beta-blockers will increase the blood concentration of this product, but do not increase the blood concentration of the antipsychotic active ingredient.
4. When taken with other highly protein-binding drugs, there is no clinically significant exchange of plasma proteins.
Pharmacological action of Risperidone.
Product method of Risperidone.
4-formyl chloro-1-acetyl piperidine and m-difluorobenzene were acylated under the catalysis of aluminum trichloride, then hydrochloric acid was used to release the acetyl group on the depiperidine ring, and the reaction with hydroxylamine was catalyzed by base to obtain benzoisoxazole derivatives. 4.4 parts of the isoxazole derivative, 5.3 parts 3-chloroethyl-2-methyl-4h-pyridine-[1, 2-α] pyrimidine-4-one hydrochloride, 8 parts sodium carbonate and 0.1 parts potassium iodide were heated in dimethylformamide at 85-90℃ with risperidone in 46% yield.
